UK markets close in 1 hour 57 minutes

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.770.00 (0.00%)
As of 03:57PM EDT. Market open.
Full screen
Loading interactive chart…
  • EQS Group

    Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval

    DGAP-News: ABIVAX / Key word(s): StudyAbivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval 04.08.2022 / 18:00 The issuer is solely responsible for the content of this announcement.ABIVAX PHASE 3 PROGRAM WITH OBEFAZIMOD IN ULCERATIVE COLITIS PROGRESSES WITH US IRB APPROVAL Phase 3 clinical induction study protocols for obefazimod in ulcerative colitis (UC) are approved by central US IRB (Institutional Review Board) Start-up activities are on track and FPI (

  • EQS Group

    Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting

    DGAP-News: ABIVAX / Key word(s): MiscellaneousAbivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting 10.06.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting Shareholders approved all proposed resolutionsPARIS, France, June 10, 2022 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotech

  • EQS Group

    Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022

    DGAP-News: ABIVAX / Key word(s): Study resultsAbivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022 01.06.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022 Pha